HCV: genedrive point-of-care test highly accurate in real-world setting

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A new handheld point-of-care test (Genedrive) meets the recent Foundation for Innovation in New Diagnostics (FIND)/WHO Target Product Profile for HCV decentralized testing in low- and middle-income countries.

Why this matters

  • HCV screening remains a key challenge to HCV eradication goals.
  • Current WHO guidelines highlight lack of field-based testing options, given the limitations of the only other approved assay (Xpert HCV).

Study design

  • French development cohort: 422 HCV+ samples, 503 HCV-negative control patients.
  • Validation cohort: 130 samples from African clinics.
  • Sensitivity/specificity were compared vs the gold standard (Abbott RealTime HCV Viral Load assay).
  • Funding: European Commission, Genedrive plc.    

Key results

  • All major genotypes were identified (limit of detection, 2362 IU/mL [95% CI, 1966-2788 IU/mL]).
  • Development cohort: results obtained on first attempt for 97.2% of samples, and 61.5% of retested samples.
    • In multivariate analysis, low HCV RNA correlated with lack of first-attempt result (P<.001>
    • Median HCV RNA: 5.9 log10 IU/mL for cases vs 2.9 log10 IU/mL for control patients.
    • Diagnostic sensitivity and specificity were 98.6% (95% CI, 96.9-99.5%) and 100% (95% CI, 99.3-100%), respectively.
  • Validation cohort: results obtained on first attempt for 95.4% of samples, and 33.3% of retested samples.
    • Diagnostic sensitivity and specificity were 100% (95% CI, 96.8%-100%) and 100% (95% CI, 73.5%-100%), respectively.

Limitations

  • Limited sample sizes.